On this episode of Stock Movers:
- Diageo (DEO) shares are lower this morning due to the company's exposure to Mexico after President Trump announced tariffs on Mexico and the European Union. Also, Bloomberg Intelligence notes the company's ambition to boost its share of the alcohol beverage market to 6% by 2030 from 4.7% looks a tough ask right now, given fragile consumer confidence and uncertainty regarding tariffs and pricing. It comes as management has withdrawn its midterm 5-7% organic-sales target.
- Novo Nordisk (NVO) is moving this morning due to its exposure to the US and tariffs. The Trump administration also proposed to consider fixed-dose combination drugs for price cuts if they don’t have a “clinically meaningful difference” compared to their original drugs. The pharmaceutical industry is resisting the proposal, with companies like Merck and Bristol Myers Squibb raising questions about the government’s legal authority and statutory basis to implement it.
- Ford (F) and General Motors (GM) are under pressure this morning. Both are moving downwards. It comes with the US recently announcing sweeping new tariffs on imports from both Mexico and the EU.
- Synopsis (SNPS) is moving this morning and at one point was the biggest upside mover in early trading. The company secured China's approval to buy out Ansys Inc. for $35 billion, according to Bloomberg. The buyout was already approved by European and US authorities, and Synopsys has now cleared one of the last major hurdles to a deal intended to shore up its market position.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Hermes declines as much as 3.3% following a downgrade to hold at Jefferies, which currently doesn’t see scope for the French luxury-goods maker to return to peak multiples. Analyst James Grzinic doesn’t model any significant acceleration in growth despite firmer US pricing and reduced availability constraints

- AstraZeneca’s experimental hypertension drug Baxdrostat reduced the blood pressure of patients who have an uncontrolled or treatment-resistant form of the condition, boosting the prospects of the medicine becoming a blockbuster. Astra has identified Baxdrostat as having potential sales of more than $5 billion a year, while Barclays estimates it could bring in about $2 billion a year when taken as a single drug. Shares of AstraZeneca rose as much as 2.1% in early trading in London.

- Brenntag shares fall as much as 5.6%, the most in almost two months, after the German chemicals firm cut its earnings guidance for the year in an unscheduled statement on Friday night. Morgan Stanley says underperformance is to be expected today, even if the profit warning wasn’t totally surprising.

See omnystudio.com/listener for privacy information.

Here are the names you should know—for better or worse—specifically for the third quarter. Bloomberg Intelligence analysts have dug into their scenarios to identify the most interesting companies from a larger group of high-confidence Focus Ideas. Spanning sectors and regions, each scenario outlines a catalyst in the next few months that supports our case.

For more on the list of companies, Paul Sweeney and Norah Mulinda speak with Tim Craighead, Director of Equity Research for Bloomberg Intelligence.

See omnystudio.com/listener for privacy information.